TREATMENT OUTCOMES OF NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) BY O6-METHYLGUANINE DNA METHYLTRANSFERASE PROMOTER (MGMT) STATUS: A MULTI-COUNTRY STUDY

被引：0
|
作者：
Fu, A. Z. [1 ,2 ]
Hall, J. P. [3 ]
Bailey, A. [3 ]
Kemp, J. [3 ]
Thompson, G. J. [4 ]
Lee, C. [1 ]
机构：
[1] Bristol Myers Squibb, Lawrenceville, NJ USA
[2] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA
[3] Adelphi Real World, Manchester, Lancs, England
[4] Bristol Myers Squibb, Uxbridge, Middx, England
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
10.1093/neuonc/noz126.265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P14.30
引用
收藏
页码：73 / 73
页数：1
相关论文
共 50 条
  • [41] Where Does O6-Methylguanine DNA Methyltransferase Promoter Methylation Assessment Place Temozolomide in the Future Standards of Care for Glioblastoma?
    Weller, Michael
    CANCER, 2018, 124 (07) : 1316 - 1318
  • [42] The Impact of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with Dacarbazine
    Cannella, Lucia
    Della Monica, Rosa
    Marretta, Antonella Lucia
    Iervolino, Domenico
    Vincenzi, Bruno
    De Chiara, Anna Rosaria
    Clemente, Ottavia
    Buonaiuto, Michela
    Barretta, Maria Luisa
    Di Mauro, Annabella
    Di Marzo, Massimiliano
    Guida, Michele
    Badalamenti, Giuseppe
    Chiariotti, Lorenzo
    Tafuto, Salvatore
    CELLS, 2023, 12 (12)
  • [43] A randomized phase II study investigating cilengitide added to standard chemoradiotherapy in patients with newly diagnosed glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Initial report of the CORE study
    Nabors, L.
    Fink, K.
    Mikkelsen, T.
    Grujicic, D.
    Tarnawski, R.
    Nam, D.
    Perry, J.
    Markivskyy, A.
    Picard, M.
    Reardon, D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S17 - S18
  • [44] A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM) - CheckMate-548
    Weller, M.
    Vlahovic, G.
    Khasraw, M.
    Brandes, A. A.
    Zwirtes, R.
    Tatsuoka, K.
    Carpentier, A. F.
    Reardon, D. A.
    van den Bent, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Comparison of pyrosequencing and methylation-specific PCR (MS-PCR) for detecting promoter methylation of O6-methylguanine DNA methyltransferase (MGMT).
    Edwards, R.
    Spittle, C.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2006, 8 (05): : 664 - 664
  • [46] CILENGITIDE IN COMBINATION WITH STANDARD TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH UNMETHYLATED O6-METHYLGUANINE- DNA METHYLTRANSFERASE (MGMT) GENE PROMOTER: KEY RESULTS OF THE OPEN-LABEL, CONTROLLED, RANDOMIZED PHASE II CORE STUDY
    Nabors, Louis Burt
    Fink, Karen L.
    Mikkelsen, Tom
    Grujicic, Dan
    Tarnawski, Rafal
    Nam, Do-Hyun
    Mazurkiewicz, Maria
    Salacz, Michael
    Ashby, Lynn
    Thurzo, Laszlo
    Zagonel, Vittorina
    Depenni, Roberta
    Perry, James R.
    Henslee-Downey, Jean
    Picard, Martin
    Reardon, David A.
    NEURO-ONCOLOGY, 2013, 15 : 80 - 80
  • [47] O6-METHYLGUANINE DNA METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION IN PRIMITIVE NEUROECTODERMAL BRAIN TUMOR (PNET) CORRELATES WITH MGMT RNA EXPRESSION AND SENSITIVITY OF PNET CELLS TO TEMOZOLOMIDE
    von Bueren, Andre
    Faoro, Denis
    Shalaby, Tarek
    Huerlimann, Marie-Louise
    Arnold, Luzia
    Gerber, Nicolas
    Haybaeck, Johannes
    Mittelbronn, Michel
    Hegi, Monika
    Rutkowski, Stefan
    Grotzer, Michael
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 825 - 825
  • [48] Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma
    Sharma, Mayur
    Bellamkonda, Sushma
    Mohapatra, Suryanarayan
    Meola, Antonio
    Jia, Xuefei
    Mohammadi, Alireza
    Angelov, Lilyana
    Barnett, Gene H.
    Vogelbaum, Michael
    Ahluwalia, Manmeet S.
    WORLD NEUROSURGERY, 2018, 116 : E147 - E161
  • [49] O6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma
    Yukihiko Sonoda
    Michiko Yokosawa
    Ryuta Saito
    Masayuki Kanamori
    Yoji Yamashita
    Toshihiro Kumabe
    Mika Watanabe
    Teiji Tominaga
    International Journal of Clinical Oncology, 2010, 15 : 352 - 358
  • [50] IN VIVO EVALUATION OF O6-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION STATUS FOR DE NOVO GLIOBLASTOMA PATIENTS USING DEEP LEARNING FEATURES
    Rathore, Saima
    Nasrallah, MacLean
    Akbari, Hamed
    Shukla, Gaurav
    Bagley, Stephen
    Watt, Christopher
    Ha, Sung Min
    Mamourian, Elizabeth
    Sako, Chiharu
    Binder, Zev
    O'Rourke, Donald
    Davatzikos, Christos
    NEURO-ONCOLOGY, 2019, 21 : 271 - 272
12345